Drug repositioning is a challenging computational problem involving the integration of heterogeneous sources of biomolecular data and the design of label ranking algorithms able to exploit the overall topology of the underlying pharmacological network. In this context, we propose a novel semisupervised drug ranking problem: prioritizing drugs in integrated biochemical networks according to specific DrugBank therapeutic categories. Algorithms for drug repositioning usually perform the inference step into an inhomogeneous similarity space induced by the relationships existing between drugs and a second type of entity (e.g., disease, target, ligand set), thus making unfeasible a drug ranking within a homogeneous pharmacological space. To deal with this problem, we designed a general framework based on bipartite network projections by which homogeneous pharmacological networks can be constructed and integrated from heterogeneous and complementary sources of chemical, biomolecular and clinical information. Moreover, we present a novel algorithmic scheme based on kernelized score functions that adopts both local and global learning strategies to effectively rank drugs in the integrated pharmacological space using different network combination methods. Detailed experiments with more than 80 DrugBank therapeutic categories involving about 1,300 FDA-approved drugs show the effectiveness of the proposed approach.

Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories / M. Re, G. Valentini. - In: IEEE/ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS. - ISSN 1545-5963. - 10:6(2013 Nov), pp. 6517183.1359-6517183.1371. [10.1109/TCBB.2013.62]

Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories

M. Re
Primo
;
G. Valentini
Secondo
2013

Abstract

Drug repositioning is a challenging computational problem involving the integration of heterogeneous sources of biomolecular data and the design of label ranking algorithms able to exploit the overall topology of the underlying pharmacological network. In this context, we propose a novel semisupervised drug ranking problem: prioritizing drugs in integrated biochemical networks according to specific DrugBank therapeutic categories. Algorithms for drug repositioning usually perform the inference step into an inhomogeneous similarity space induced by the relationships existing between drugs and a second type of entity (e.g., disease, target, ligand set), thus making unfeasible a drug ranking within a homogeneous pharmacological space. To deal with this problem, we designed a general framework based on bipartite network projections by which homogeneous pharmacological networks can be constructed and integrated from heterogeneous and complementary sources of chemical, biomolecular and clinical information. Moreover, we present a novel algorithmic scheme based on kernelized score functions that adopts both local and global learning strategies to effectively rank drugs in the integrated pharmacological space using different network combination methods. Detailed experiments with more than 80 DrugBank therapeutic categories involving about 1,300 FDA-approved drugs show the effectiveness of the proposed approach.
Drugs ; Algorithm design and analysis ; Bipartite graph ; Bioinformatics ; Diseases ; Databases ; Graph nodes ranking ; Drug ranking ; Drug repositioning ; Networks integration ; kernel functions ; systems biology
Settore INF/01 - Informatica
Settore ING-INF/05 - Sistemi di Elaborazione delle Informazioni
nov-2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
re-vale-ISBRA-TCBB-rev2.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 526.48 kB
Formato Adobe PDF
526.48 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/232521
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 33
social impact